Endocrine Manifestations of HIV Infection by Adamu Girei, Bakari & Fatima, Sani-Bello
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 11
Endocrine Manifestations of HIV Infection
Bakari Adamu Girei and Sani-Bello Fatima
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52684
1. Introduction
Human Immune deficiency Virus (HIV) infection has assumed pandemic proportion since
after its identification as the causative agent of Acquired Immunodeficiency Syndrome
(AIDS).The spectrum of HIV infection and AIDS is quite wide and variable. HIV infected
patients have an increased risk of developing endocrine abnormalities [1]. The endocrine
glands are affected in a variety of ways such as functional derangement, direct effects of
HIV infection and the resultant immune suppression, effects of opportunistic infections both
acute and chronic, invasion by neoplasms and the effects of the various medications used to
treat HIV or any of the opportunistic infections associated with it (Table 1). While endocrine
dysfunction has not been a prominent clinical feature of AIDS, all endocrine glands may be
affected by the opportunistic infections and malignancies; as a result of antiretroviral treat‐
ment or indeed as a result of the direct invasion of the glands by the virus (Table 2). The
introduction of anti-retroviral (ARV) drugs has significantly reduced both morbidity and
mortality attributable to HIV infection [2]. The prolonged administration of these drugs
however, has led to new challenges for both physicians and patients [3- 8].
Apart from the effects of acute and chronic illnesses, the relentless progression of immune
dysfunction in AIDS affects endocrine function through the activation of several cytokines,
chemokines and antibody formation. The use of protease inhibitors (PIs) and nonnucleoside
reverse transcriptase inhibitors (NNRTIs) is associated with multiple abnormalities in glu‐
cose and lipid metabolism such as insulin resistance, increased triglycerides and increased
levels of low-density lipoprotein cholesterol. These metabolic disturbances might be due to a
combination of factors, including the direct effect of medications, restoration to health; HIV
disease as well as individual genetic predisposition. Of the available antiretroviral medica‐
tions, indinavir had been associated with causing the most insulin resistance and ritonavir
with causing the most hypertriglyceridemia.
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a. Destruction of endocrine tissue
• Cancer
• Infection
• Haemorrhage
• Non-specific inflammation
b. Interference with Endocrine function
• Acute illness
• Chronic illness
• Cytokines (tumour necrosis factor, interleukin-1, interferon)
• Antibodies
c. Effects of medications
• ARV’s
• Anti Tuberculosis drugs.
• Antifungal drugs.
• Antiviral drugs.
• Antibiotics.
Table 1. Mechanisms of Endocrine dysfunction in patients with HIV [1]
a. Endocrinopathies as a result of direct effects of the virus.
• HIV adrenalities and impaired adrenal reserve
• Hypercorticolism
• Idiopathic adrenohypophyseal necrosis
• Hyperprolactinaemia
• Primary hypogonadism
• Growth factor
• AIDS wasting syndrome
b. Endocrinopathies as a resultof structural destruction of gland.s
• Cytomegalovirus (CMV) adrenalitis
• Pneumocystis thyroiditis
• Mycobacterial infection, cryptococcosis, toxoplasmosis(pituitary, thyroid, adrenals)
• Haemorrhages and abscesses causing insufficiency of glands (pituitary, thyroid and adrenals)
Table 2. Common Endocrine abnormalities in HIV infected patients [1].
2. The pituitary
Involvement of the pituitary gland is common in advanced HIV infection, at autopsy; varying
degrees of infarction and necrosis are the most common findings occurring in nearly 10% of
cases [1]. Also common are opportunistic Infections by CMV, Pneumocystis carinii, Toxoplas‐
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mosis and mycobacteria among others [9]. Furthermore, the pituitary may also be affected by
neoplasms such as cerebral lymphoma with peripheral involvement of the gland.
Despite the foregoing, evaluation of anterior pituitary reserve in HIV infected patients by
TSH or gonadotropin stimulation has demonstrated a normal response in nearly all patients.
Suggesting that panhypopituitarism is rare in these patients.
GH deficiency does not appear to be common [1]. Posterior pituitary function may be al‐
tered in HIV patients with Hyponatremia occurring in up to 50% of inpatients and about
20% of outpatients with AIDS; two-thirds of these patients are clinically euvolemic with se‐
rum arginine vasopressin levels that are inappropriately high for the serum osmolality, con‐
sistent with the syndrome of inappropriate antidiuretic hormone secretion [10 - 12]. The
presence of Pneumocystis carinii pneumonia and/ or treatment with trimethoprim appears
to be the most significant risk factors for this complication. Furthermore, central diabetes in‐
sipidus has been reported in AIDS patients with herpetic meningoencephalitis.
3. Thyroid dysfunction
Although thyroid function tests are often abnormal in HIV patients, the prevalence of overt
thyroid disorder is not significantly different from that of the general population [13]. Most
asymptomatic patients with HIV infection have normal thyroid function. Some, however, ex‐
hibit increased serum total thyroxine (T4) and triiodothyronine (T3) concentrations. These in‐
creases are as a result of increases in serum thyroxine-binding globulin, the cause of which is
unknown [14]. However, with progression of HIV infection and as the patients become more
ill, serum T4 and T3 concentrations decline, as is obtained in most if not all chronically ill pa‐
tients; serum thyrotropin concentrations however remain normal or slightly depressed. These
changes are as a result of reduction in serum binding proteins, decreased extrathyroidal con‐
version of T4 to T3, and decreased secretion of thyrotropin [13], [14]. Cytokines may be in‐
volved in some of these; especially the reduction in the peripheral conversion of T4 to T3 [15].
An increasing number of patients taking anti-HIV drugs are presenting with thyroid disor‐
ders as a result of improved immune function (immune reconstitution syndrome). Graves’
disease is the commonest among immune reconstitution syndromes; others include Hashi‐
moto’s thyroiditis and hypothyroidism. Autoimmune Thyroid Disease (AITD) occurs in 3%
of women and 0.2% of men [13- 17]. Goddard proposed a staging of autoimmune manifesta‐
tions related to HIV/AIDS (table 3) [18].
The prevalence of immune reconstitution Autoimmune Thyroid Disease (AITD) (Graves’
disease, Hashimoto thyroiditis, and hypothyroidism) is about 3% for women and 0.2% for
men. Patients with lower CD4 counts at baseline with greater increments in the CD4 counts
following HAART are more likely to develop AITD.
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Stage Features
Stage I Acute HIV infection, the immune system is intact and autoimmune diseases may develop.
Stage II The quiescent period without overt manifestations of AIDS associated with a declining
CD4 count indicative of some immunosuppression. Autoimmune diseases are not found.
Stage III Immunosuppression with low CD4 count and the development of AIDS. CD8 T cells
predominate and diseases such as psoriasis and diffuse immune lymphocytic syndrome
(similar to Sjogren’s syndrome) may present or even be the initial manifestation of AIDS.
No autoimmune diseases are found.
Stage IV Restoration of immune competence following HAART. In this setting, there is a
resurgence of autoimmune disorders.
Table 3. Stages of autoimmune manifestations in HIV/AIDS.
Thyroid dysfunction in HIV-positive individuals can result from gland destruction by op‐
portunistic pathogens such as Pneumocystis jirovecii which has been reported to cause a
painful low uptake thyroiditis like picture with hyperthyroidism followed by hypothyroid‐
ism. Other opportunistic pathogens that could affect the thyroid gland in HIV infected indi‐
viduals include Cryptococcus neoformans, Aspergillosis and cytomegaloviurs [19 - 23]. The
gland may also be invaded by Kaposi Sracoma with resultant hypothyroidism [24].
Overt Hypothyroidism should be treated with levothyroxine keeping in mind that drug in‐
teractions between levothyroxine and protease inhibitors have been reported, perhaps
through the shared metabolic pathway of glucuronidation. In subclinical hypothyroidism
however, the TSH level should be determined again within three months as the levels nor‐
malize within a year in up to 30% of affected patients. In cases of overt hyperthyroidism, it
is paramount to establish whether it is as a result of Graves’ disease, or thyroiditis and the
appropriate therapy instituted.
4. Adrenal dysfunction
Biochemical evidence of adrenal insufficiency is relatively common in hospitalized AIDS pa‐
tients occurring in almost a fifth of such patients however, only about 4% are clinically
symptomatic patients [25]. Adrenal dysfunction may be suspected in HIV-infected patients
with advanced stage of AIDS. High index of suspicion is required; subtle impairment of
adrenal function is manifested as fatigue, hyponatremia or rarely with clinical symptoms of
adrenal insufficiency. At autopsy, the adrenal gland shows evidence of both inflammation
and necrosis1, [26 - 28]. Adrenal secretion of aldosterone and adrenal androgens may also be
impaired. In fact, there appears to be a shift from adrenal androgen and aldosterone produc‐
tion toward glucocorticoid production. However, the secretion of aldosterone in response to
assumption of the upright posture and the administration of angiotensin II is normal. The
mechanisms by which HIV might affect adrenal secretion appear to be dependent on effects
of cytokines and other immunomodulatory substances on the hypothalamo-pituitary-adre‐
nal axis [29 - 32]. The potential sites of immune modulation of this is shown in this figure 1.
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Interleukin-1 is a likely candidate as either a direct or an indirect adrenal stimulator. Its pro‐
duction by macrophages is stimulated by tumor necrosis factor, and the production by mac‐
rophages of both interleukin-1 and tumor necrosis factor is stimulated by HIV infection [33].
Interleukin-1 may affect the hypothalamus, pituitary, or adrenal glands in a variety of ways
[29]. Interleukin-1 stimulates the release of corticotropin-releasing hormone from the hypo‐
thalamus into the portal circulation leading to the increases in corticotropin and consequent‐
ly cortisol secretion. Furthermore, Interleukin-1 has been shown to directly stimulate
cultured pituitary cells to release corticotropin. Cultured adrenocortical cells secrete more
cortisol when cocultured with mononuclear cells most likely as a result of a response to the
production of interleukin-1 by mononuclear cells [30 - 32]. Interferon, another product of
HIV-infected monocytes and macrophages, is also an immunomodulator of the hypothala‐
mo-pituitary-adrenal axis [34].
Figure 1. Effects of cytokines on the Hypothalamo-pituitary-adrenal axis.
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Both interleukin-1 and interferon thus have effects that could stimulate adrenal function.
Conversely, adrenal function could be inhibited in patients with HIV infection as a result of
polyclonal B-cell activation and the production of anti—adrenal-cell antibodies. The specific
cellular or hormonal antigenic determinants and the pathogenetic importance of these anti‐
bodies are unclear. In addition to these mechanisms of adrenal dysfunction in patients with
HIV infection, drugs which impair adrenal function directly such as Ketoconazole which in‐
hibits adrenal steroidogenesis, Rifampicin, phenytoin, and opiates which accelerate the deg‐
radation of cortisol and therefore lower serum cortisol concentrations are frequently
prescribed in HIV infected patients. Although the resulting need for increased cortisol secre‐
tion is easily met in normal subjects, it may not be so in patients with HIV infection.
5. Glucocorticoids
The adrenal corticosteroids ( Cortisol and Aldosterone), exert profound influences on many
physiologic functions by virtue of their diverse roles in growth, development and mainte‐
nance of homeostasis [35]. The actions of these corticosteroids are mediated by intracellular
receptor proteins, the glucocorticoid (GR) and mineralocorticoid (MR) receptors respective‐
ly. These receptors act as hormone-activated transcription factors which regulate the expres‐
sion of the glucocorticoid and mineralocorticoid target genes respectively. The GR is
ubiquitous and is found in virtually all human tissues and organs [1, 35].
Glucocorticoids are essential to maintain the integrity of central nervous system and cardio‐
vascular function,as well as the maintenance of metabolic and immune function.
Tissue hypersensitivity to glucocorticoids was recently hypothesized in patients with Hu‐
man Immunodeficiency Virus type-1 infection via the accessory proteins Vpr and Tat which
enhance GR transactivation [36]. Since HIV-1 long terminal repeat (LTR) and glucocorticoid-
responsive promoters use the same set of co-activators, these proteins may stimulate HIV-1-
LTR and glucocorticoid-inducible genes concurrently. The former may directly stimulate
viral proliferation, while the latter may indirectly enhance viral propagation by suppressing
the host immune system through glucocorticoid mediated mechanisms.
6. Glucocorticoid hypersensitivity in AIDS
AIDS patients have several manifestations compatible with tissue hypersensitivity to gluco‐
corticoids [37]. Some of the manifestations include reduction of innate and cellular immuni‐
ty mediated through T helper 1 cells with resultant reduction in the secretion of interleukin
(IL)-2, IL-12 and interferon and increased secretion of IL-4. These changes are similar to
what obtains when exogenous glucocorticoids are administered as well as in hypercortisole‐
mic patients with endogenous Cushing’s syndrome. Furthermore, hippocampal atrophy
similar to what is observed in individuals who exhibit hypercortisolism is seen in HIV in‐
fected patients especially in pediatric AIDS patients. Other features seen in HIV/AIDS pa‐
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tients that are similar to features of hypercortisolism include muscle wasting and myopathy,
dyslipidemia and visceral obesity and insulin resistance. From the foregoing, it seems possi‐
ble that some unknown factor(s) modulate tissue sensitivity to glucocorticoids in HIV infect‐
ed patients.
The observed glucocorticoid hypersensitivity in HIV infected patients seem to preferentially
affect the brain, fat cells, the liver, the musculoskeletal system and the immune system. It is
noteworthy that the hypothalamo-pituitary-adrenal axis is not affected suggesting that ap‐
propriate negative feedback sensitivity to glucocorticoids is preserved.
There is evidence to suggest that glucocorticoid hypersensitivity in HIV/AIDS is mediated
through one of the HIV-1 accessory proteins the virion-associated protein (Vpr). This is a 96
amino acid protein with multiple functions. This protein is known to act as a transcriptional
activator of several viral promoters and as an enhancer of HIV-1 long terminal repeat pro‐
moter activated by Tat as well as enhances the replication of HIV-1 virus in lymphocyte-
and monocyte-derived cell lines. Furthermore, the protein also increases the translocation of
the HIV-1 pre-integration complex into the nucleus promoting efficient infection of non-di‐
viding macrophages.
The protein circulates in HIV-1-infected individuals and has the capacity to penetrate cell
membranes. This suggests that its effects have the potential to involve all cells including
those not infected by HIV-1. It is indeed this protein that has been shown by Kino et al [36]to
increase the tissue sensitivity to glucocorticoids by functioning as a coactivator of the GR on
its responsive promoters. By inducing hypersensitivity to glucocorticoids, these proteins
contribute to the proliferation of the virus indirectly by suppressing the host immune sys‐
tem. Extensive further clinical and basic investigations are crucial to examine the clinical im‐
portance of glucocorticoid hypersensitivity and to develop novel effective therapeutic
approaches in AIDS.
Although the involvement of the adrenal gland is common in HIV patients, routine screen‐
ing is not however recommended as adrenal insufficiency is a relatively rare complication of
HIV infection. Its presence should however be considered, however, in those with dissemi‐
nated cytomegalovirus infection or tuberculosis. It should also be suspected, in patients with
otherwise unexplained symptoms and signs compatible with adrenal insufficiency, such as
anorexia, nausea, weight loss, and fatigue, and especially in patients with more specific
manifestations of adrenal insufficiency, such as postural hypotension, hyponatremia, or hy‐
perkalemia. It is also reasonable to be concerned about adrenal reserve in patients who are
about to undergo major stress, such as surgery. The simplest test is to measure the serum
cortisol concentration in the morning, when it is highest in normal subjects. A concentration
of 10 μg per deciliter (280 nmol per liter) or less suggests the presence of adrenal insufficien‐
cy. However, higher cortisol concentrations do not rule out the possibility of diminished
adrenal reserve. If the basal serum cortisol concentration is low or the suspicion of adrenal
insufficiency persists, provocative testing with corticotropin is indicated. Such testing in‐
volves measuring the serum cortisol concentration before and 30 and 60 minutes after the
intravenous or intramuscular administration of 0.25 mg of cosyntropin. The cortisol concen‐
tration should increase by at least 7 μg per deciliter (196 nmol per liter) at 30 minutes and 11
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μg per deciliter (308 nmol per liter) at 60 minutes. Alternatively, a normal response is a con‐
centration twice the basal value at 60 minutes. Whether one considers the extent of a change
in the cortisol concentration or the multiple of the basal value, the peak stimulated value
should be 18 μg per deciliter (504 nmol per liter) or more for the response to be considered
normal [48, 49]. Glucocorticoid therapy should be given only in cases of documented adre‐
nal insufficiency or when there is a medical emergency in which the possibility of adrenal
crisis cannot be excluded.
7. Gonadal dysfunction in male
Male gonadal dysfunction is common among AIDS patients. With more than two-thirds of
male patients with advanced HIV disease exhibit of loss of libido and up to one-third of
them having erective dysfunction [38, 39]. The prevalence and severity of male gonadal dys‐
function is directly proportional to disease severity. In advanced disease stages, biochemical
hypogonadism is found in up to half of male AIDS patients. With the advent of HAART, the
prevalence of male gonal dysfunction has reduced to about 20% among those receiving
HAART [40]. Gonadal dysfunction in HIV/AIDS is usually attributable to secondary causes
such as the effect of under nutrition, infection-inflammation and several drugs on gonado‐
tropin production. Other secondary causes include the role of cytokines produced in re‐
sponse to systemic illness may impair the secretion of gonadotropin-releasing hormone or
gonadotropin [41]. Low levels of interleukin-1 enhance testicular steroidogenesis in vitro,
whereas higher doses inhibit the binding of gonadotropin to Leydig cells and steroidogene‐
sis by these cells. Ketoconazole used in the treatment of fungal infections in HIV/AIDS pa‐
tients inhibits gonadal as well as adrenal steroid production and could therefore also
contribute to the observed gonadal dysfunction.
Furthermore, hyperprolactinaemia and gynecomastia have been reported among HIV-in‐
fected patients [42]. Prolactin has for long been known to be an immunostimulatory hor‐
mone and is also known to be elevated in other immunostimulatory states such as systemic
lupus erythematosis (SLE). Similarly, prolactin receptors are found in T and B lymphocytes
as well as monocytes [43], while lymphocytes are known to produce a prolactin like protein.
The men with low serum testosterone concentrations may have inappropriately normal se‐
rum gonadotropin concentrations, suggesting involvement of the pituitary gland or hypo‐
thalamus however, there is neither CT scans nor autopsy data provide evidence of pituitary
or hypothalamic disease.
As sex hormone binding capacity increases in up to a third of HIV patients, the use of free
testosterone assay is recommended for diagnosis. [38] Physiologic testosterone replacement
that does not suppress endogenous gonadal function results in increased lean body mass,
improved quality of life and reduction in depression. Standard therapy for hypogonadism
has been intramuscular testosterone (enanthate or ciprionate esters) every 1–3 weeks to pro‐
vide 100 mg per week. Alternate transdermal or oral routes for androgen administration are
also available. Prostate-specific antigen level should be monitored in elderly patients receiv‐
ing testosterone.
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8. Gonadal dysfunction in female
Ovarian dysfunction among female AIDS patients is less common. Amenorrhoea is seen in
about a quarter of women during stress of illness; while failure of ovulation is seen among
half of the female patients with low CD4 counts [44]. Early menopause has been seen in up
to 8% of HIV-infected female patients. Androgen deficiency has been reported especially in
women with significant weight loss. The reasons for the above observations are not clear,
but could be as a result of intra-adrenal shunting toward cortisol production from androgen
synthesis. Human chorionic gonadotropin levels suggest intact ovarian androgen produc‐
tion. Delivery of low doses of testosterone using transdermal patches improves functional
capacity without hirsuitism or virilisation but does not increase lean body mass [38].
9. Glucose homeostasis in HIV/AIDS
Normal glucose metabolism is largely dependent on normal insulin secretion, insulin sensi‐
tivity and to a lesser extent on the influences of other hormones and cytokines. Before the
advent of highly active anti-retroviral therapy (HAART), HIV infection on its own was
thought to be protective against the development of diabetes mellitus1, this may be due to
the following observations in clinically stable, symptomatic HIV-infected patients. These in‐
dividuals have been shown to have higher rates of insulin clearance and increased sensitivi‐
ty of peripheral tissues to insulin as well as an increase in noninsulin-mediated glucose
uptake. The increase in glucose uptake is predominantly accounted for by an increase in
non-oxidative glucose disposal.
Pancreatic abnormalities are common in AIDS patients as a result of opportunistic infections
and malignancies1. However, the majority of these lesions are not extensive enough to cause
clinically significant pancreatic dysfunction. Clinically significant pancreatic dysfunction is
usually as a result of therapeutic interventions; noteworthy in this regard is Pentamidine
[45], which is used in the management of Pneumocystis carinii and may cause pancreatic β-
cell toxicity with resultant hypoglycaemia in the acute phase and some of these patients may
later develop diabetes mellitus.
With the advent of HAART however, a new dysmetabolic syndrome with substantially in‐
creased risk for cardiovascular events emerged [46]. This syndrome has variable expressibil‐
ity; and includes insulin resistance, visceral adiposity, peripheral lipodystrophy,
dyslipidaemia and glucose intolerance. Several studies have demonstrated an increased risk
of diabetes among HIV infected individual on HAART especially when protease inhibitors
(PIs) are included in the regimen. Among HIV infected minority patients in the USA for ex‐
ample, the prevalence of diabetes after three years of PI therapy was 12%, compared to none
among those not receiving PI’s4. However, although PI’s are the most frequent agents associ‐
ated with metabolic complication, there are evidences to suggest that virtually all classes of
agents used in ART has the potential to cause metabolic derangements. Although the mech‐
anism by which ART drugs induce these metabolic changes are not fully clear; it has been
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shown that indinavir, a PI dramatically inhibits glucose uptake in a dose dependent manner
in adipocytes by selectively inhibiting the Glut-4 transporter function [47]. Furthermore,
there is evidence at least in laboratory studies to show that indinavir down regulates the
peroxisome proliferator–activated receptor -γ (PPAγ) receptor in adipocytes [48]. Obviously
some genetic predisposition could explain why not all patients on PI’s develop diabetes, or
any of the other metabolic complications.
10. Bone mineral dysfunction
Both osteoporosis and osteopenia are common among AIDS patients. Reduced bone mineral
density is seen in almost three quarter of HIV-infected patients compared to about 30% in
HIV-negative individuals of similar age [49]. Reduced vertebral bone density is associated
with visceral adiposity among HIV-infected patients. Similarly, reduced bone density also
occurs in HIV-infected children receiving HAART with maximum reduction seen among
those with lipodystrophy. Several factors are thought to be responsible for the observed ef‐
fects on the skeleton. The effects of low GH and IGF1, hypogonadism and excess visceral
adiposity are possible factors as they have been found to correlate significantly with verte‐
bral bone density [50 - 52]. Protease Inhibitors are also known to induce relative vitamin D
deficiency and may also act as an additive factor.
11. Calcium and vitamin D balance
Hypocalcemia is common in HIV infected patients occurring in more than 5% of them [53].
It appears the level of calcium has an inverse relationship with the stage of the disease and
its severity. Factors responsible for hypocalcaemia in these patients include vitamin D defi‐
ciency and reduced parathyroid hormone (PTH ) level. The cause of the relatively reduced
PTH is not known but may be as a result of the effects of cytokines; and presence of hypo‐
magnesemia which is relatively common among HIV infected patients especially those with
chronic diarhoea. On the other hand, the cause of Vitamin D deficiency is multifactorial in
the setting of HIV/AIDS and may include malabsorption, decreased hydroxylation as a re‐
sult of the effects of protease inhibitors. Furthermore, several therapeutic agents such as fo‐
scarnet, pentamidine, and ketoconazole, may affect calcium homeostasis [53].
Hypercalcemia is uncommon in AIDS. When present it is likely to be due to infectious, ma‐
lignant, or granulomatous processes [54 - 55]. Patients with lymphoma who have hypercal‐
cemia typically have increased serum 1,25-dihydroxyvitamin D concentrations, because the
tumors contain vitamin D 1-hydroxylase and therefore convert 25-hydroxyvitamin D to
1,25-dihydroxyvitamin D. Cultured lymphoma cells infected with HIV have the same syn‐
thetic activity. Human T-cell lymphotropic virus Type I (HTLV-I), a retrovirus linked to T-
cell leukemia and lymphoma may be associated with hypercalcemia. Increased bone
resorption in this syndrome may be due to lymphokines such as interleukin-2 or to parathy‐
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roid hormone-related protein. A HTLV-I gene product, tax,has been implicated in the activa‐
tion of the parathyroid hormone-related protein gene. Serum concentrations of parathyroid
hormone and 1,25-dihydroxyvitamin D are not elevated in HTLV-I—related hypercalcemia.
12. AID wasting syndrome
Wasting is an age-old terminal event of AIDS, even with the advent of HAART, wasting re‐
mains common affecting more than one-third of patients [57]. Unfortunately, weight loss is a
significant predictor of mortality in HIV infection. Those with a body mass index (BMI) of
less than 18.4 kg/M2 are at 2.2-fold increased risk of mortality, while those with a BMI less
than 16 kg/M2 are at 4.4-fold increased risk of mortality [58].
Currently, AIDS wasting syndrome is defined as body weight less than 90% of ideal weight
or weight loss of more than 10% of body weight over 3 months. The condition is character‐
ised by a disproportionate loss of lean body mass with a relative sparing of body fat as the
disease progresses this is associated with muscle wasting, weakness, increased resting ener‐
gy expenditure and hypertriglyceridemia. The exact mechanisms involved in the aetiology
of this condition are not clear. However, the roles of Cytokine related increased energy ex‐
penditure and decreased appetite, diarrhoea, malabsorption and hypogonadism are likely
mechanisms behind such wasting [59, 60].
Management of this condition include optimal antiretroviral therapy and adequate nutri‐
tion. Testosterone (intramuscular/transdermal) has been successfully used to increase lean
body mass in men with this syndrome, whereas it has also been shown to be safe and well
tolerated in women. A number of agents like anabolic steroids (oxandrolone, nandrolone),
megesrtol acetate, thalidomide, human chorionic gonadotropin, pentoxyfiline, amino acid
mixtures and omega 3 fatty acids have been tried in this setting with variable efficacy but
potential side effects. Only testosterone administration has proved useful to increase lean
body mass, especially in conjunction with progressive resistance training. Administration of
supraphysiologic doses of growth hormone is currently reserved for severe wasting refrac‐
tory to other treatments.
13. HIV lipodystrophy syndrome
HIV lipodystrophy syndrome is associated with metabolic derangements, changes in body
composition and abnormal fat distribution. It has been most widely recognized since the era
of HAART but can also be seen in antiretroviral-naïve patients [61]. It is characterized by
phenotypic changes similar to those observed in Cushing’s syndrome, such as like truncal
obesity, buffalo hump, peripheral fat loss, atrophy of facial fat and breast enlargement in
women. Considering some physical similarities to Cushing's syndrome, it has been termed
as “a pseudo-Cushing's syndrome” though no other specific stigmata of Cushing's syn‐
drome (proximal muscle weakness, bruising and facial plethora) nor biochemical parame‐
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ters are associated with this syndrome. Normal cortisol level with its normal diurnal
variation and adequate suppressibility to dexamethasone are also seen in HIV lipodystro‐
phy syndrome. However, it is very often associated with insulin resistance, hyperglycemia,
and hypertriglyceridemia. In particular, dyslipidemia and diabetes mellitus are increasingly
common among patients receiving HAART. management consist of exercise and lifestyle
modification, switching to less-toxic NRTIs or PIs, fenofibrates to decrease serum triglycer‐
ide level, and use of insulin sensitizers like metformin to reduce visceral fat and thiazolidi‐
nediones to improve subcutaneous fat loss. Testosterone and anabolic steroids have no
effect in reducing visceral fat in this syndrome.
14. Conclusion
Although HIV endocrinopathy is common, overt glandular failure is a rare clinical entity.
HIV infection, acting by a number of mechanisms, may be responsible for subtle clinical and
not-so-subtle biochemical abnormalities. Drug-induced endocrine toxicity is important
cause of endocrinopathy in HIV infected patients.
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